![]() Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancerĪntazoline Hydrochloride & Tetryzoline HydrochlorideĪntazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL Reduction of elevated platelet counts in patients with essential thrombocythaemia who are intolerant to their existing therapy or for whom other therapies are not considered appropriate PAH associated with connective tissue diseaseĪmiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mgĪmoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mgĪmoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mLĪmoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg.Treatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies: Treatment of locally advanced or metastatic ALK mutation-positive non-small cell lung cancerĪlendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international unitsġ) For patients with osteoporosis (T-score ≤ -2.5)Ģ) For patients with osteopenia (T-score ≤ -1.5) and a history of non-trauma induced fractureĪluminium Hydroxide, Magnesium Trisilicate & SimeticoneĪluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mgĪluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL Treatment of locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer ![]() Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice.Ģ) Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. Pre/perimenopausal women treated with this combination could also receive a luteinizing hormone-releasing hormone agonist according to local clinical practice.ġ) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.Ģ) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.ģ) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mgġ) Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |